SCHEMBL30165339

SCHEMBL30165339

C=CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2ccc(NC(=O)c3cccc(-c4ccn[nH]4)n3)nc2)C1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 7/20 0.53
MAP3K19 Q56UN5 1/20 0.50
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
TP53 P04637 4/20 0.44
PKM P14618 2/20 0.44
GRM5 P41594 2/20 0.44
IRAK4 Q9NWZ3 2/20 0.43
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
PTBP1 P26599 1/20 0.40
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.37
ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23860709 1.00 IRAK1 (0.53) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL20206223 0.91 IRAK1 (0.63) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL30165336 0.91 IRAK1 (0.63) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL23860749 0.91 IRAK1 (0.63) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL20206130 0.91 IRAK1 (0.63) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL30165338 0.89 IRAK1 (0.53) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL23860746 0.89 IRAK1 (0.53) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL30279677 0.87 IRAK1 (0.51) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL27084620 0.87 IRAK1 (0.51) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2
SCHEMBL23860732 0.84 IRAK1 (0.48) IRAK1MAP3K19NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4125895-A1 POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 Dana-Farber Cancer Institute, Inc. (US) 2023-02-08 EP disclosed